Search results
Refer to the recommended dosing and administration information for each indication when prescribing ELIQUIS® to patients. See Indications and Important Safety Information, including Boxed WARNINGS.
Dose adjustment for NVAF patients: 2.5 mg twice daily is recommended in patients with at least 2 of the following characteristics: • age ≥80 years • body weight ≤60 kg • serum creatinine ≥1.5 mg/dL ELIQUIS® (apixaban) DOSING SUMMARY Indication Recommended dosing
31 lip 2024 · The recommended dose of ELIQUIS is 2.5 mg twice daily in patients with at least two of the following characteristics: •. age greater than or equal to 80 years. •. body weight less than or equal to 60 kg. •. serum creatinine greater than or equal to 1.5 mg/dL.
podawania produktu Eliquis i VKA należy oznaczyć wskaźnik INR przed następnym zaplanowanym podaniem dawki produktu Eliquis. Jednoczesne podawanie produktu Eliquis i VKA należy kontynuować do czasu, aż wartość wskaźnika INR wyniesie ≥ 2. Pacjenci w podeszłym wieku
If cardioversion is required before 5 doses of apixaban can be administered, a 10 mg loading dose should be given, followed by 5 mg twice daily. The dosing regimen should be reduced to a 5 mg loading dose followed by 2.5 mg twice daily if the patient meets the criteria for dose reduction (see above sections Dose reduction and Renal impairment ...
Posology. Prevention of VTE (VTEp): elective hip or knee replacement surgery. The recommended dose of apixaban is 2.5 mg taken orally twice daily. The initial dose should be taken 12 to 24 hours after surgery. as well as the risks of post-surgical bleeding in deciding on the time of administration within this t.
In patients already taking ELIQUIS at a dose of 2.5 mg twice daily: Avoid coadministration with combined P-gp and strong CYP3A4 inhibitors. See below for additional dosing information, including dose adjustments and important dosing considerations for ELIQUIS.
